Company intelligence / Profile preview
Safi Biotherapeutics
Cambridge, Massachusetts, United Statessafi.bio ↗
- Ownership
- Private
- Employees
- ~25
- Development stage
- Other
01
Overview
Safi Biotherapeutics is developing on-demand, lab-grown red blood cells and other blood products to address shortages and provide alternatives for patients with chronic transfusion needs. The company’s lead programs are in pre-clinical development, with initial proof-of-concept studies demonstrating the feasibility of producing functional, enucleated red blood cells at scale. No clinical results have been reported yet.
- Therapeutic areas
- Hematology
- Modalities
- Cell therapyRecombinant proteinInduced pluripotent stem cell derived therapy
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Department of Defense / U.S. government program for on-demand blood manufacturingAdvanced Regenerative Manufacturing Institute (ARMI)Massachusetts General Hospital (MGH)
Beyond the preview
Go deeper on Safi Biotherapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Safi Biotherapeutics.